ClinicalTrials.gg
CompletedNCT01779947Updated Jun 26, 2014

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

A Phase 3 interventional study of Estradiol Vaginal Tablets 10 mcg and placebo in Atrophic Vaginitis Due to Menopause, sponsored by Amneal Pharmaceuticals, LLC. Completed at 25 sites in United States. Open to female participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-06-26.

Sponsored by Amneal Pharmaceuticals, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
519
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Atrophic Vaginitis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Atrophic Vaginitis · United States.

Enrollment
5th of 23
519 · median 69
Started
2012
the only one that year
Phase 3
11 of 23
none open now
Registered
9th of 23
by date
Lead sponsor
1 of 23
Amneal Pharmaceuticals, LLC

Among the 23 studies in Atrophic Vaginitis with a site in United States, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 11 in phase 3, and was the 9th registered.

Atrophic Vaginitis

45 studies on the registry are indexed under Atrophic Vaginitis; 7 are open to participants now.

Browse Atrophic Vaginitis studies →

Open to participants now

2 of the 23 studies in Atrophic Vaginitis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Atrophic Vaginitis studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 30 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Atrophic Vaginitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of generic Estradiol Vaginal Inserts, USP 10 mcg to the reference product Vagifem® 10 mcg and to determined whether the efficacy of each of the 2 active treatments is superior to that of the placebo.

03

Conditions studied

  • Atrophic Vaginitis Due to Menopause

Browse trials for

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide and understand written for the study.
  • Healthy female subject aged 30 to 75 years, inclusive, who was , defined as having had 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  • At least 1 subject-assessed moderate to severe symptom of VVA among the following 4 symptoms that was identified by the subject as being most bothersome to her:
  • Vaginal dryness
  • Vaginal and/or vulvar irritation/itching
  • Dysuria
  • Vaginal pain associated with sexual activity OR
  • The presence of vaginal bleeding associated with sexual activity
  • Had ≤ 5% superficial cells on vaginal smear cytology at Visit 1.
  • Vaginal pH > 5.0 at Visit 1.
  • Systolic blood pressure ≤ 150 mm Hg and diastolic blood pressure ≤ 90 mm Hg at Visit 1.
  • If > 40 years old, documentation of a negative mammogram (obtained at Visit 1 or within 9 months prior to Visit 1). A radiology report documenting a negative mammogram must have been available and must have been taken within 9 months of Visit 1 or obtained at Visit 1.
  • Normal clinical breast examination at Visit 1.
  • For women with intact uterus, vaginal ultrasonography confirmation at Visit 1 of an inactive endometrial lining, with an endometrial thickness \< 4 mm.
  • Documented Pap smear conducted within the previous 12 months of Visit 1 with no findings that the investigator believed would contraindicate the use of topical vaginal estradiol.
  • In general good health with no disease other than symptoms of VVA that might have interfered with the study evaluations.
  • Was willing and able to understand and comply with the requirements of the study, including applying the medication as instructed, returning for the required study visits, complying with therapy prohibitions, and able to complete the study.

Exclusion criteria

Exclusion Criteria:

  • Known to estradiol vaginal tablet or any component of the study medication.
  • A subject who had received any treatment listed below more recently than the indicated prior to Visit 1/Screening/Baseline.
  • Prohibited Medications - (Washout Period Prior to Visit 1/Screening/Baseline)
  • Vaginal lubricants or moisturizers - (at least 48 hours (2 days))
  • Vaginal hormonal products (rings, creams, gels) - (at least 1 week (7 days))
  • Transdermal estrogen alone or estrogen/progestin products - (at least 4 weeks (28 days))
  • Oral estrogen and/or progestin therapy - (at least 8 weeks (56 days))
  • Intrauterine progestin therapy - (at least 8 weeks (56 days))
  • Progestin implants and estrogen alone injectable drug therapy - (at least 3 months (90 days))
  • Estrogen pellet therapy or progestin injectable drug therapy - (at least 6 months (180 days))
  • Subject who had engaged in sexual intercourse within 48 hours (2 days) of Visit 1.
  • Screening mammogram or clinical breast examination results indicating any suspicion of breast .
  • History of undiagnosed vaginal bleeding.
  • Known bleeding disorder.
  • History of significant risk factors for endometrial cancer (i.e., tamoxifen use, prior pelvic radiation therapy, and endometrial hyperplasia).
  • For women with an intact uterus, screening vaginal ultrasonography showing endometrial thickness of ≥ 4 mm.
  • Known, suspected, or history of breast cancer or cervical cancer.
  • Known or suspected estrogen-dependent neoplasia.
  • History of uncontrolled hypertension.
  • Active deep vein thrombosis, pulmonary embolism, or history of these conditions.
  • Active arterial thromboembolic disease (e.g., stroke or myocardial infarction) or a history of these conditions.
  • Known liver dysfunction or disease.
  • Known anaphylactic reaction or angioedema to estradiol vaginal tablets.
  • Known protein C, protein S, antithrombin deficient, or other known thrombophilic disorders. - Active vaginal herpes simplex infection or any known concurrent vaginal infections.
  • Abnormal Pap smear within the previous 12 months of Visit 1 or obtained during Visit 1. Any evidence of malignancy or premalignant changes or atypical squamous cell of undetermined significance (ASCUS) Pap smear with positive high risk human papillomavirus (HPV).
  • Any condition or situation (including laboratory values) other than the condition being studied that, in the opinion of the investigator, would have interfered with the study evaluations or optimal participation in the study.
  • Use of any drugs or device within 30 days of signing the ICF.
  • Current participation in any other clinical study involving an investigational drug or device.
  • Consumed excessive amounts of alcohol, abused drugs, or had any condition that would have compromised compliance with this protocol.
  • Previous participation in this study.
  • Subjects who, in the opinion of the Investigator, would have been non-compliant with the requirements of the study protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
519 participants (actual)

Study arms

  • Experimental
    Estradiol Vaginal Insert 10 mcg

    Estradiol Vaginal Insert 10 mcg - Test Product

    Drug: Estradiol Vaginal Tablets 10 mcg

  • Active comparator
    Vagifem Tablets 10 mcg

    Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug

    Drug: Estradiol Vaginal Tablets 10 mcg

  • Placebo comparator
    Placebo

    Placebo for the test product Estradiol Vaginal Tablets 10 mcg

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Responders

    A responder was defined as a subject with at least a 25% reduction from baseline in the sum of % basal/parabasal and % intermediate cells on vaginal cytology AND vaginal pH \< 5.0 with a change from baseline vaginal pH of at least 0.5, where baseline values were collected at Visit 1

    Time frame: Day 15 (1 day after the administration of the 14th dose of study treatment)

Secondary outcomes

  1. Treatment Success

    Treatment success was defined as a subject who achieved a score of 0 (none) or 1 (mild) at Visit 3 for the Most Bothersome Symptom (MBS) if her MBS was vaginal dryness, vaginal or vulvar irritation or itching, dysuria or vaginal pain associated with sexual activity, or a result of absence (0) at Visit 3 if her MBS was vaginal bleeding with sexual activity.

    Time frame: Day 15

07

Study locations

25 sites
  • Medical Affiliated Research center, Inc.
    Huntsville, Alabama 35801, United States
  • Montogmery Women's Health Associates
    Montgomery, Alabama 36117, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Women's Health Care Research Corp.
    San Diego, California 92123, United States
  • Downtown Women's Health care
    Denver, Colorado 80218, United States
  • Horizons Clinical Research Center
    Denver, Colorado 80220, United States
  • James A. Simon, MD PC/ Women's Health and Research Consultants
    Washington, District of Columbia 20036, United States
  • Visions Clinical Reserach
    Boynton Beach, Florida 33472, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • New Age Medical Reserach Group
    Miami, Florida 33186, United States
  • Comprehensive Clinical Trials, LLC
    West Palm Beach, Florida 33409, United States
  • Atlanta North Gynecology
    Roswell, Georgia 30075, United States
  • Mount Vernon Clinical Research, LLC
    Sandy Springs, Georgia 30328, United States
  • Cypress Medical Research Center. LLC
    Wichita, Kansas 67226, United States
  • Meridian Health Care
    Neptune, New Jersey 07753, United States
  • Center for Women's Health and Wellness, LLC/ Women's Health Research Center
    Plainsboro, New Jersey 08536, United States
  • Premier Medical Group of the Hudson Valley
    Poughkeepsie, New York 12601, United States
  • Lyndhurst Clinical Research
    Raleigh, North Carolina 27607, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Hawthorne Medical Research, Inc.
    Winstom-Salem, North Carolina 27103, United States
  • Lyndhurst Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Columbus Center for Women;s Health Reserach
    Columbus, Ohio 43213, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Seatlle Womne's Health,Reserach, Gynecology
    Seattle, Washington 98105, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Sep 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2013
First posted
Jan 30, 2013
Start
Mar 2012
Primary completionActual
Sep 2012
CompletionActual
Dec 2012
Results delay requested
Jun 25, 2014
Last update
Jun 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01779947
Responsible party
Sponsor
First posted
Jan 30, 2013
Start date
Mar 2012
Primary completion
Sep 2012
Completion
Dec 2012
Last update
Jun 26, 2014

Study contacts

W. Todd Kays, PhD
study chair · Amneal Pharmaceuticals, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion